Translational Research in Pediatric and Obstetric Pharmacology (R21)

The summary for the Translational Research in Pediatric and Obstetric Pharmacology (R21) Federal Grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the government agency that is offering this grant.
Federal Grant Title: Translational Research in Pediatric and Obstetric Pharmacology (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-11-248
Type of Funding: Grant
CFDA Numbers: 93.865
CFDA Descriptions: Child Health and Human Development Extramural Research
Current Application Deadline: May 15, 2013
Original Application Deadline: May 15, 2013
Posted Date: Jul 12, 2011
Creation Date: Jul 12, 2011
Archive Date: Jun 15, 2013
Total Program Funding:
Maximum Federal Grant Award: $275,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Grant Description
The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and/or in pregnant women and the developing fetus. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/par-11-248.html
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Obstetric-Fetal Pharmacology Research Centers (OPRC) (U54)
Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcom...
Medically Assisted Reproduction: Investigation of Mechanisms Underlying the Adverse Outcom...
Pharmacogenetics, Pharmacoepigenetics and Personalized Medicine in Children (R01)
Innovative Therapies and Tools for Screenable Disorders in Newborns (R03)
Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...
Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...
Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health
Paul B. Beeson Patient-Oriented Research Career Development Award in Aging (K23)
Paul B. Beeson Clinical Scientist Development Award in Aging (K08)
Bioreactors for Reparative Medicine (R43/R44)
Bioreactors for Reparative Medicine (R41/R42)
Bioreactors for Reparative Medicine - SBIR Direct Phase II (R44)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2014 FederalGrants.com